lestaurtinib

fms related receptor tyrosine kinase 3 ; Homo sapiens







32 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33623141 FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. 2021 May 5
2 33846544 Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. 2021 May 1
3 31919472 FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. 2020 Mar 1
4 32441887 Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction. 2020 Jul 6
5 30681373 Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors. 2019 Mar 1
6 31528345 Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. 2019 1
7 31648336 Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. 2019 Oct 22 1
8 30514344 FLT3 inhibitors in acute myeloid leukemia. 2018 Dec 4 1
9 27872058 A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. 2017 Mar 2 4
10 27450971 FLT3 Inhibitors for Treating Acute Myeloid Leukemia. 2016 Oct 1
11 26547689 Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. 2015 Nov 7 7
12 26625890 Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. 2015 Dec 1
13 24883179 The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. 2014 Jun 2
14 23294096 MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism. 2013 Mar 1
15 21263155 FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. 2011 Mar 24 2
16 21270442 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. 2011 Mar 24 3
17 20141349 Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. 2010 Mar 2
18 21082990 Lestaurtinib: a multi-targeted FLT3 inhibitor. 2009 Feb 2
19 18217204 A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. 2008 Jun 1
20 18271064 Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. 2008 Jun 1
21 18341639 Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication. 2008 May 2
22 17359372 FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. 2007 Apr 2
23 17442779 Effect of FLT3 inhibition on normal hematopoietic progenitor cells. 2007 Jun 2
24 16761017 Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner. 2006 Aug 2
25 16857985 A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. 2006 Nov 15 4
26 16868253 The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. 2006 Nov 15 2
27 15374878 FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. 2005 Jan 15 4
28 15574429 FLT3/ITD mutation signaling includes suppression of SHP-1. 2005 Feb 18 1
29 16105978 Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. 2005 Dec 1 2
30 14726387 Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. 2004 May 15 2
31 15126317 In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. 2004 Aug 15 2
32 12010785 A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. 2002 Jun 1 2